Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer
Clinical trial NCT01111825 · COMPLETED
Trial details
- NCT number
- NCT01111825
- Sponsor
- Puma Biotechnology, Inc.
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2010-04-01
- Primary completion
- 2016-07-01
- Enrollment
- 99
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.